Skip to content

Clinical efficacy observation of microelectronic meridian point modulation technology based intervention in knee osteoarthritis

Clinical efficacy observation of microelectronic meridian point modulation technology based intervention in knee osteoarthritis

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400088256
Enrollment
Unknown
Registered
2024-08-14
Start date
2024-09-01
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoarthritis of the knee

Interventions

Microelectronic analgesic Group:Microelectronic analgesic instrument plus millimetre needle acupuncture on the affected side of the Liangqiu, Sea of Blood, Yanglingquan, Yinlingquan, Foot Sanli, Sanyi
G6805-D electro-acupuncture Group:G6805-D type electroacupuncture instrument plus millimetre needle acupuncture on the affected side of Liangqiu, Sea of Blood, Yanglingquan, Yinlingquan, Foot Sanli, S

Sponsors

Third Affiliated Hospital of Henan University of traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Those who meet the above western medical diagnostic criteria; (2) Those who are 50-75 years old (including 50 and 75 years old); (3) Those with VAS score =4; (4) Those who voluntarily signed the informed consent and were willing to actively cooperate with the treatment; Patients included in this study must meet all 4 of the above conditions at the same time.

Exclusion criteria

Exclusion criteria: (1) Those with other painful diseases in combination, such as rheumatism, rheumatoid disease, trauma, tumour, tuberculosis, etc; (2) Those with a history of knee surgery or indications for surgery, e.g., arthroscopic surgery, artificial joint replacement, etc; (3) Those who have a recent history of knee trauma or skin breakage or infection near the knee joint; (4) Pregnant women, lactating women, allergic or allergic to the study treatment drugs; (5) Combined cardiovascular, cerebrovascular, hepatic, renal, respiratory, digestive, endocrine, haematopoietic system and other serious primary diseases; (6) Those with systemic infection or suffering from infectious diseases; (7) Those with cognitive impairment and mental illness, etc. who are unable to sign the informed consent form and complete the scale; (8) Those who are conducting other clinical trials at the same time. Patients who meet any 1 of the above 8 criteria should be excluded.

Design outcomes

Primary

MeasureTime frame
Bioelectric signal;

Secondary

MeasureTime frame
Visual Analogue Scale;Western Ontario and McMaster University;Lysholm knee score;

Countries

China

Contacts

Public ContactCaiyonggang; Zhouyoulong

Third Affiliated Hospital of Henan University of traditional Chinese Medicine

unravel186@qq.com+86 193 0389 2225

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026